US 12,233,157 B1
Hydrogel formulations and methods and devices for administration of the same
Tomasz Pawel Stryjewski, Somerville, MA (US); James Anthony Stefater, III, Boston, MA (US); Laurence A. Roth, Windham, NH (US); and Kelsey-Ann Leslie, Cambridge, MA (US)
Assigned to PYKUS THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Pykus Therapeutics, Inc., Cambridge, MA (US)
Filed on Jul. 24, 2024, as Appl. No. 18/783,305.
Int. Cl. A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 31/25 (2006.01); A61K 31/795 (2006.01); A61K 47/54 (2017.01)
CPC A61K 9/0051 (2013.01) [A61K 9/06 (2013.01); A61K 31/25 (2013.01); A61K 31/795 (2013.01); A61K 47/548 (2017.08)] 17 Claims
 
1. A method of contacting retinal tissue in an eye of a subject, the method comprising:
injecting into the vitreous cavity of the eye of the subject an effective amount of a nucleo-functional polymer and an electro-functional polymer; and
allowing the nucleo-functional polymer and the electro-functional polymer to react to form a hydrogel in the vitreous cavity, which hydrogel contacts the retinal tissue in the eye, thereby providing a retinal tamponade;
wherein the nucleo-functional polymer is a biocompatible polymer comprising hyaluronic acid containing a plurality of thio-functional —R1—SH, wherein R1 is hydrolyzable, and the electro-functional polymer is a biocompatible polymer comprising poly(ethylene glycol) containing at least one thiol-reactive group.